K

Kiniksa Pharmaceuticals Ltd
D

KNSA

62.470
USD
-1.02
(-1.61%)
قبل الجلسة·62.440USD-0.030(-0.05%)
حجم التداول
400
الربح لكل سهم
1
العائد الربحي
-
P/E
69
حجم السوق
4,806,317,860
أصول ذات صلة المقالات
المزيد

العنوان: Kiniksa Pharmaceuticals International plc

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.